PRAMIPEXOLE GxP pramipexole dihydrochloride 0.25 mg tablets blister pack

Land: Australien

Sprache: Englisch

Quelle: Department of Health (Therapeutic Goods Administration)

Wirkstoff:

pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg

Verfügbar ab:

Arrotex Pharmaceuticals Pty Ltd

INN (Internationale Bezeichnung):

pramipexole dihydrochloride monohydrate

Darreichungsform:

Tablet, uncoated

Zusammensetzung:

Excipient Ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide

Verabreichungsweg:

Oral

Einheiten im Paket:

10, 30, 100

Verschreibungstyp:

(S4) Prescription Only Medicine

Anwendungsgebiete:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.

Produktbesonderheiten:

Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Berechtigungsstatus:

Licence status A

Berechtigungsdatum:

2014-09-23